

# NERVIANO MEDICAL SCIENCES

## Nerviano Medical Sciences Srl Appoints Dr. Tomasz Rzymiski as Chief Scientific Officer

**NERVIANO, Italy, May 5, 2025** — Nerviano Medical Sciences Srl (NMS), global leader in oncological innovation, is proud to announce the appointment of Dr. Tomasz Rzymiski as its new Chief Scientific Officer (CSO), effective immediately.

Dr. Tomasz Rzymiski joins NMS with over 20 years of experience in scientific research, innovation leadership, and R&D management. As CSO, he will oversee the research team and the company's research programs aiming at delivering unprecedented projects to the clinical stage.

"We are thrilled to welcome Dr. Rzymiski to our executive team," said [Hugues Dolgos](#), Pharm.D., CEO of NMS "With a distinguished career in oncology drug discovery his deep scientific acumen and proven leadership will be instrumental as we continue to innovate and scale our research efforts."

Prior to joining NMS, Dr. Rzymiski served as Head of Translational Medicine and member of the Executive Board at Ryvu Therapeutics, where he led groundbreaking research resulting in first-in-class experimental drugs entering clinical trials. Earlier in his career, he held academic and research positions at the Technical University of Munich and University of Oxford and Cancer Research UK. He has authored over 100 scientific publications, is an inventor on seven patents, and is recognized for driving impactful oncology R&D across discovery and translational medicine.

"I'm honored to join NMS at such an exciting time," said Dr. Rzymiski "The team's dedication to scientific excellence and transformative impact aligns perfectly with my passion for advancing cutting-edge research. I look forward to accelerating our innovation pipeline and delivering meaningful breakthroughs for patients."

Dr. Rzymiski holds a Ph.D. in Molecular Biology from the Georg-August-Universität Göttingen, Germany and an Executive MBA from the Cracow University of Economics in Poland. He has built an extensive academic foundation through prior roles at the Oxford University, Cancer Research UK and the Technical University of Munich. Over the last 15 years at Ryvu Therapeutics, he held executive leadership positions, advancing multiple drug discovery projects and overseeing the company's biology and translational medicine departments.

This appointment marks a key milestone in NMS's continued investment in world-class science and its mission to bring oncology forward.

---

### About Nerviano Medical Sciences

[Nerviano Medical Sciences S.r.l.](#) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.

NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. A core strength lies in our

# NERVIANO MEDICAL SCIENCES

renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including with encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.

Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets

For more information, visit <https://www.nervianoms.com>.

**Media Relations:** [sidney.dung@nervianoms.com](mailto:sidney.dung@nervianoms.com)